Astellas Pharma Inc. and Sutro Biopharma Inc. signed an exclusive global licensing deal under which Sutro will develop immunostimulatory antibody-drug conjugates (iADCs) for three biological targets for Astellas. Read More
London-based Invox Pharma Ltd. has announced plans to acquire F-star Therapeutics Inc. for $161 million to build up the presence of its parent company, Sino Biopharm Ltd., outside of China. Read More
A tightening of rules for biotech listings on the Shanghai STAR Market may have contributed to a visible cool-down in biotech IPOs, with fewer listings in Chinese stock markets in the first half of 2022. Read More
The U.S. FDA has placed a clinical hold on Astellas Pharma Inc.’s Fortis phase I/II trial evaluating AT-845 following a serious adverse event of peripheral sensory neuropathy in one of the trial participants. AT-845 is an adeno-associated virus (AAV) gene replacement therapy being studied in adults with late-onset Pompe disease. Read More
Japan’s Ministry of Health, Labour and Welfare has given Otsuka Holdings Co. Ltd. subsidiary Taiho Pharmaceutical Co. Ltd. the green light for its oral heat shock protein 90 (HSP90) inhibitor Jeselhy (pimitespib) to treat gastrointestinal stromal tumors (GIST) that have progressed after chemotherapy. The company will soon commercialize the drug in Japan. Read More
Tessa Therapeutics Ltd. has a closed a $126 million series A financing round to advance its ongoing clinical development, which includes the initiation of a pivotal trial of autologous CD30-CAR-T therapy (TT-11) and advancement of allogeneic CD30.CAR EBVST therapy (TT-11X) programs. Read More
Nonprofit deals with biopharma companies in 2022 indicate that 92% of the disclosed funds are going toward infectious disease therapies, with COVID-19 accounting for 79% of the total. Read More
As a growing roster of nations moves to protect individual genomic and other health data in the name of privacy under the General Data Protection Regulation in the EU and similar laws elsewhere, chief aggregators of such data, drug developers, are struggling. Read More
In a rare move, Australia’s Therapeutic Goods Administration is allowing two prescription-only COVID-19 treatments to be advertised to the public. Read More
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: 60 Degrees, Akston, Bharat, Biolexis, GSK, Innocare, Kinarus, Moderna, Ocugen, Recce, Sanofi. Read More
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Ainos, Antengene, Antisense, Beigene, Cortexyme, Cullinan Oncology, Degron, Dr. Reddy’s, Eton, F-star, Innovation, Kinarus, Kuria, Medicinova, Scohia, Sino, Taiho. Read More
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Acepodia, Alterity, Basilea, Beigene, Biomarin, Daewoong, Daiichi Sankyo, Eli Lilly, Eyepoint, Hoth, Innovent, Kyowa Kirin, Moderna, Novavax, Ocumension, Valneva. Read More
